Business Wire

NV-ARMIS

6.8.2024 14:01:31 CEST | Business Wire | Press release

Share
Armis Surpasses $200M ARR, Doubling ARR in Less Than 18 Months

Black Hat Armis, the asset intelligence cybersecurity company, announced today that it has surpassed $200m in annual recurring revenue (ARR), doubling its ARR in less than 18 months and making it one of just a few companies that have achieved this rapid scale, not just in the cybersecurity market, but of any SaaS company worldwide.

Armis’ explosive growth has been driven by its award-winning AI-powered cyber exposure management platform, Armis Centrix™, which has been adopted by the world’s leading organizations, including 35 of the top Fortune 100 companies. Customers like United Airlines, the U.S Postal Service, Ryanair, Mondelez, Reckitt and Flex trust Armis to help them secure their most critical environments. Great demand from national, state, local and Federal entities has led to increased deployment of Armis’ solutions globally. Armis also saw continued momentum across North America, EMEA and APJ which has led Armis to double its ARR in less than 18 months.

“This significant milestone reflects not just our huge financial growth in the last year but shows the unwavering trust that Fortune 100, 200, and 500 companies, large private organizations and healthcare systems, and governments place in us to safeguard their mission critical assets & infrastructure,” said Yevgeny Dibrov, Co-Founder and CEO at Armis. “Our commitment to empowering businesses with robust asset intelligence and security, proactive defense strategies and full risk management has never been stronger. As we continue to expand our impact across industries, this milestone fuels our mission to ensure that every organization can operate confidently in the face of evolving threats.”

Armis’ mission is to protect organizations' entire attack surface by managing cyber risk exposure in real time. Its cloud-based platform Armis Centrix™ and its suite of solutions proactively mitigate all cyber asset risks by identifying every asset, from the ground to the cloud, remediating vulnerabilities and blocking threats to give organizations peace of mind that all critical assets are protected.

Demand for Armis’ award-winning platform Armis Centrix™ continues at a rapid pace. Armis has expanded its capabilities & offerings, with the back to back acquisitions earlier this year of CTCI and Silk Security. Armis Centrix™ product suites now include deeper vulnerability mitigation, prioritization, remediation, risk management and threat intelligence. It has developed a world-class partner first approach and seen expansion with some key partnerships over the last few years such as Accenture, Blackwood, Booz Allen Hamilton, CDI, Fortinet, GuidePoint Security, HCl, KPMG, Nomios, Optiv, Presidio, PWC, Softcat, Source IT Technologies, Telia Cygate, WWT and the AWS and Google Marketplaces.

“Over the past year we have been laser focused on efficient growth, expansion of customer engagement, adoption of our platform Armis Centrix™️, its 5 product suites, and have focused more on expanding our channel partner engagement,” said Jonathan Carr, Chief Financial Officer of Armis. “With our recent acquisitions and expanded capabilities, we continue to see high demand for our platform, its products and are growing well in excess of top public company benchmarks, in addition to our own industry peers.”

“Armis is an integral part of Main Line Health’s cybersecurity program, providing unparalleled visibility into every asset and device within our environment,” said Aaron Weismann, Chief Information Security Officer at Main Line Health. “As a hospital system dedicated to delivering safe, high-quality, equitable and affordable care to treat and cure disease, Armis allows us to focus on what truly matters.”

Industry analysts have recognized Armis’ broad platform offering with Frost & Sullivan awarding Armis two Best Practices awards - Customer Value Leadership for OT Cybersecurity and Technology Innovation Leadership for Global Healthcare Cybersecurity.

Additional industry analyst firm recognition:

The Forrester Wave™: Operational Technology Security Solutions, Q2 2024, “Armis is ideally suited for organizations needing to manage a diverse and sprawling IoT and OT environment.”

Manuel Alborez, Frost & Sullivan Best Practices Research Analyst, “The Armis Centrix™ platform’s overarching distinction is that, through a single pane of glass, it provides a real-time, contextual view of the environment and security posture, monitoring and managing all assets affecting patient care, including IT, OT, IoT, medical devices, enterprise assets, and cloud infrastructure. In addition to this robust visibility, Armis offers cutting-edge threat intelligence and forensic monitoring capabilities.”

Danielle VanZandt, Frost & Sullivan Industry Manager – Commercial & Public Security, “In the face of a sprawling IT, OT, and IoT ecosystem, Armis provides its customers with the centralized management needed to protect their businesses. As organizations shift away from network-centric security, Armis acknowledges the potential vulnerability of any asset type. This enables them to guide security teams in proactive mitigation efforts, safeguarding the robustness of essential business processes across various sectors.”

Chris Ray, GigaOm Analyst, “Armis is a formidable player in the ASM landscape, focusing on asset discovery and management. At its core, the platform utilizes a dual-method approach for asset discovery: integration-based discovery for known assets and deep packet inspection (DPI) of network traffic to unearth everything else.

Additional analyst recognition and awards have been received in the last 12 months and are a testament to Armis’ award-winning Armis Centrix™ platform and approach to customer success:

Recent awards in the last year are as follows:

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806677978/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye